Instrument Inactif

Communiqués TCR2 Therapeutics Inc.

Actions

TCRR

US87808K1060

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

TCR2 THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	24/05/23	AQ
TCR2 Therapeutics : Merger Agreement - Form 8-K	23/05/23	PU
TCR-2 THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE	12/05/23	AQ
TCR2 THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	11/05/23	AQ
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update	11/05/23	GL
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08/05/23	GL
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08/05/23	AQ
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, ROCC, TCRR	27/04/23	PR
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR	26/04/23	BU
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ROCC, KBAL, ADAP, TCRR	11/04/23	PR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RADI, ADAP, TCRR	06/04/23	PR
TCR-2 THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	04/04/23	AQ
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/04/23	GL
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/04/23	AQ
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROCC, RADI, ADAP, TCRR	28/03/23	PR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSEY, ADAP, TCRR	23/03/23	PR
TCR2 THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23/03/23	AQ
TCR2 THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23/03/23	AQ
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update	23/03/23	GL
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update	23/03/23	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués TCR2 Therapeutics Inc.

Actions

TCRR

US87808K1060

Communiqués

Filtres